Clinical trials: Apixaban
Atrial Fibrillation (AF)
Prediction of Systemic Thromboembolism and Bleeding in Atrial Fibrillation Patients With Factor Xa Inhibitor (Apixaban, Rivaroxaban) by Echocardiographic Parameters: Prospective Observational Study (AF-ECHO Study)
Patients taking Factor Xa inhibitors (Apixaban, Rivaroxaban) in atrial fibrillation will be conducted a follow-up investigation on systemic embolism and bleeding events.
- Trial name
- NCT06779695
- Where
- South Korea
- Volunteers
- 2,000 people
- Sponsor
- Korea University Anam Hospital
Venous Thromboembolic Disease, Kidney Failure, Chronic
Anticoagulation Strategies for Acute Venous Thromboembolism in Patients With End-Stage Renal Disease Using USRDS Data
Patients with end stage renal disease (ESRD) are at significantly increased risk of thrombosis and bleeding relative to those with normal renal function which makes anticoagulation particularly challenging.
- Trial name
- NCT04818151
- Testing
- Warfarin, Apixaban
- Where
- United States
- Volunteers
- 14,914 people
- Sponsor
- Johns Hopkins University
Nonvalvular Atrial Fibrillation
Evaluation of Hospital Readmissions Among Hospitalized Non-valvular Atrial Fibrillation (NVAF) Patients in the US
The overall objective of this proposal is to execute a real-world database analysis to evaluate hospital readmissions among hospitalized nonvalvular atrial fibrillation (NVAF) patients in the U.S Primary objective: To determine…
- Trial name
- NCT02674594
- Volunteers
- 30,000 people
- Sponsor
- Bristol-Myers Squibb
ESRD, Anticoagulant Toxicity
Apixaban in End-stage Kidney Disease : A Pharmacokinetics Study
Apixaban is a novel oral direct factor Xa inhibitor; In patients with atrial fibrillation, apixaban was superior to warfarin in preventing stroke or systemic embolism, caused less bleeding, and resulted in lower mortality (the…
- Trial name
- NCT03456648
- Testing
- apixaban
- Where
- Belgium
- Volunteers
- 24 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Pharmacokinetics, Kidney Transplant
Drug Interaction Study of Apixaban With Cyclosporine or Tacrolimus in Transplant Recipients
This study aims to evaluate the pharmacokinetics (PK) of apixaban in kidney and lung transplant recipients stabilized on either cyclosporine or tacrolimus as part of their immunosuppressive therapy.
- Conditions
- Pharmacokinetics, Kidney Transplant, Lung Transplant
- Trial name
- ACT-KLR (NCT04023760)
- Testing
- Apixaban
- Where
- Canada
- Volunteers
- 14 people
- Sponsor
- University of Saskatchewan
VTE Prophylaxis With Anticoagulation After Total Knee Replacement Surgery
A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee Replacement Surgery
The primary purpose of Part 1 in this study is to assess the safety and tolerability of JNJ-64179375 for each dose level for dose escalation and any bleeding events (the composite of major, clinically relevant non-major, and…
- Trial name
- TEXT-TKR (NCT03251482)
- Testing
- JNJ-64179375 0.3 mg/kg, JNJ-64179375 0.6 mg/kg, JNJ-64179375 1.2 mg/kg
- Where
- 103 sites in United States, Argentina and 14 more
- Volunteers
- 308 people
- Sponsor
- Janssen Research & Development, LLC
Anticoagulation
A Study to Assess the Effects of 2 Prothrombin Complex Concentrates on the Pharmacodynamics of Apixaban in Healthy Adult Subjects
The purpose of this study is to assess the effect of two 4-Factor PCC formulations on Apixaban pharmacodynamics in healthy adult subjects.
- Trial name
- NCT02074358
- Testing
- Apixaban, Cofact (4-Factor PCC), Beriplex P/N (4-Factor PCC)
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Acute Coronary Syndrome (ACS)
Safety Study of Apixaban in Recent Acute Coronary Syndrome
The purpose of this clinical research study is to determine whether apixaban will be safe in people who have recently had unstable angina or a heart attack.
- Trial name
- NCT00313300
- Testing
- Apixaban
- Where
- 151 sites in United States, Austria and 12 more
- Volunteers
- 1,741 people
- Sponsor
- Bristol-Myers Squibb
Atrial Fibrillation, Atrial Flutter
Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation
The trial seeks to determine if apixaban, an investigational anticoagulant (blood-thinner) is as effective as standard therapy (warfarin) in preventing stroke and systemic embolism in subjects with atrial fibrillation and risk…
- Trial name
- ARISTOTLE (NCT00412984)
- Testing
- warfarin, apixaban
- Where
- 1,111 sites in United States, Argentina and 39 more
- Volunteers
- 20,976 people
- Sponsor
- Bristol-Myers Squibb
Atrial Fibrillation, End Stage Renal Disease
Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
This is a prospective, randomized, open-label, blinded end-point evaluation trial. The patient population consists of patients on hemodialysis who have atrial fibrillation (AF) and end-stage renal disease (ESRD) .
- Trial name
- RENAL-AF (NCT02942407)
- Testing
- apixaban, warfarin
- Where
- 58 sites in United States
- Volunteers
- 154 people
- Sponsor
- Christopher Granger, MD
Transient Ischemic Attack, Stroke
Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation
The purpose of this study is to evaluate if Apixaban will decrease the complication of having another stroke for people who have atrial fibrillation if initiated earlier than standard of care.
- Conditions
- Transient Ischemic Attack, Stroke, Atrial Fibrillation
- Trial name
- AREST (NCT02283294)
- Testing
- Apixaban, Warfarin
- Where
- 5 sites in United States
- Volunteers
- 91 people
- Sponsor
- University of South Florida
Coronary Artery Disease, High On-treatment Platelet Reactivity (HTPR)
Effect of Two Weeks of Low-Dose Apixaban on Platelet Reactivity in Patients With Stable Coronary Artery Disease on Dual Antiplatelet Therapy (Aspirin and Clopidogrel)
The goal of this clinical trial is to learn whether a low dose of apixaban, a blood-thinning medicine, changes how active the platelets are in adults with stable coronary artery disease who are already taking aspirin and…
- Trial name
- ACER (NCT07853612)
- Testing
- Apixaban
- Where
- Trinidad and Tobago
- Volunteers
- 16 people
- Sponsor
- The University of The West Indies
Cancer-associated Thrombosis
API-CAT STUDY for APIxaban Cancer Associated Thrombosis
The main objective is to determine whether a low-dose regimen of apixaban (2.5 mg bid) is non inferior to a full-dose regimen of apixaban (5 mg bid) for the prevention of recurrent venous thromboembolism (VTE) in patients with…
- Trial name
- API-CAT (NCT03692065)
- Testing
- Apixaban 5 MG
- Where
- 114 sites in Austria, Belgium and 9 more
- Volunteers
- 1,766 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Obesity, Morbid
Bariatric Surgery and Pharmacokinetics of Apixaban
Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines.
- Trial name
- NCT03448783
- Testing
- Apixaban
- Where
- Norway
- Volunteers
- 12 people
- Sponsor
- Norwegian University of Science and Technology
Random Allocation, Intermittent Fasting
Pivotal BE Study of TAH3311 ODF vs ELIQUIS® Tablet Under Fasted Condition in Healthy Volunteers
This single-dose, open-label, randomized, four-way crossover study evaluates the pharmacokinetics, safety, and tolerability of TAH3311 5 mg in healthy volunteers under fasted and fed conditions.
- Conditions
- Random Allocation, Intermittent Fasting, Enteral Feeding
- Trial name
- NCT06689436
- Testing
- 5 mg Apixaban Oral Dissolving Film (fasting), 5 mg Apixaban Oral Dissolving Film (fed), 5 mg Apixaban Oral Tablet (US RS/RLD)
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- TAHO Pharmaceuticals Ltd.
Atrial Fibrillation, Stroke Prevention in Patients With Atrial Fibrillation
CLOT-LESS - CLOsure Tailored: LEss Antithrombotic Strategy After LAAC for Stroke Prevention
This is a prospective, non-randomized, observational cohort study conducted at the FSBI "NMRC TPM" of the Ministry of Healthcare of the Russian Federation.
- Conditions
- Atrial Fibrillation, Stroke Prevention in Patients With Atrial Fibrillation, Left Atrial Appendage Closure, Hemorrhage
- Trial name
- CLOT-LESS (NCT07575867)
- Testing
- Left Atrial Appendage Closure, Apixaban 2.5 mg BID, Standard-dose DOAC
- Where
- Russia
- Volunteers
- 464 people
- Sponsor
- National Medical Research Center for Therapy and Preventive Medicine
Atrial Fibrillation
A Phase 2 Study To Evaluate The Safety Of Apixaban In Atrial Fibrillation
To assess the effect of two doses of Apixaban (2.5 mg BID and 5 mg BID) versus Warfarin on the composite endpoint of major and clinically relevant non-major bleeding during the treatment period.
- Trial name
- NCT00787150
- Testing
- Apixaban, Warfarin sodium
- Where
- 18 sites in Japan
- Volunteers
- 222 people
- Sponsor
- Pfizer
Acute Coronary Syndrome, Atrial Fibrillation
APixaban vs. PhenpRocoumon in Patients With ACS and AF: APPROACH-ACS-AF
It is hypothesised that a dual therapy strategy by oral anticoagulation with the new Factor-Xa-inhibitor apixaban plus clopidogrel is superior to a triple therapy regimen with phenprocoumon plus acetylsalicylic acid (ASA) and…
- Conditions
- Acute Coronary Syndrome, Atrial Fibrillation, Coronary Artery Disease
- Trial name
- APPROACH (NCT02789917)
- Testing
- Dual Therapy, Triple Therapy
- Where
- 16 sites in Germany
- Volunteers
- 403 people
- Sponsor
- LMU Klinikum
Venous Thromboembolism, Cancer
Apixaban for the Prevention of Venous Thromboembolism in Cancer Patients
Cancer patients have an increased risk of developing blood clots in the veins compared to non-cancer patients. Cancer patients who develop blood clots can lead to reduced life expectancy, delayed cancer treatment, and decreased…
- Trial name
- AVERT (NCT02048865)
- Testing
- Apixaban
- Where
- 14 sites in Canada
- Volunteers
- 575 people
- Sponsor
- Ottawa Hospital Research Institute
Neoplasms Malignant, Surgery
Improved Adherence With Extended Venous Thromboembolism Prophylaxis After Major Cancer Surgery
This is a prospective, twin-center, cohort study in patients discharged from the hospital after major abdominal or pelvic cancer surgery for cancer.
- Conditions
- Neoplasms Malignant, Surgery, Venous Thromboembolism, Prophylaxis
- Trial name
- NCT04479579
- Testing
- Apixaban 2.5 milligram
- Where
- 2 sites in Canada
- Volunteers
- 53 people
- Sponsor
- McMaster University